Enveric Biosciences, Inc. (ENVB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Enveric Biosciences, Inc. (ENVB) closed at USD 1.37 on 2026-10-14, a change of -80.8 % over the past year, with a market capitalization of USD 6.22M.

Enveric Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Enveric Biosciences, Inc. key figures

Previous close

USD 1.37 (2026-10-14)

1-year change

-80.8 %

Market cap

USD 6.22M

Enterprise value

USD -2.07M

P/E ratio (trailing)

-0.11

P/E ratio (forward)

-0.99

EPS (trailing)

-13.10

EPS (forward)

-1.41

PEG ratio

n/a

Price to book

0.68

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.25

Employees

5

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Enveric Biosciences, Inc.

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Enveric Biosciences, Inc. and compare it with other stocks.